Non-alcoholic steatohepatitis (NASH) is a common liver disease that can progress to liver fibrosis, cardiovascular disease, and cancer. In the absence of any approved treatments for it, there is a pressing need for new, effective drugs. In NASH Unmet Need 2017, hepatologists and gastroenterologists reveal the attributes that drive their prescribing and how current treatment options compare across efficacy and safety attributes. Using the Target Product Profile Simulator, we establish physicians’ preference for emerging drugs and assess if these drugs can capitalize on the untapped NASH space.
- What are the treatment drivers and goals for NASH?
- What attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for NASH?
- What are the prevailing areas of unmet need and opportunity in NASH?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European hepatologists and gastroenterologists for a hypothetical new NASH drug?
- Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European hepatologists and gastroenterologists fielded in February 2017.
Key companies: Takeda, Merck KGaA, Intercept, Genfit
Key drugs: Actos, Glucophage, Ocaliva, Elafibranor